HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.
HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.
HONG KONG – Home to large populations and steadily growing economies, Asia is poised to serve as an important growth region for pharmaceuticals for decades to come.
HONG KONG – Home to large populations and steadily growing economies, Asia is poised to serve as an important growth region for pharmaceuticals for decades to come.
HONG KONG – China's government-founded Guangzhou Institutes of Biomedicine and Health (GIBH) has partnered with a U.S. biotech company to co-develop its cancer candidate.
HONG KONG – China's government-founded Guangzhou Institutes of Biomedicine and Health (GIBH) has partnered with a U.S. biotech company to co-develop its cancer candidate.
HONG KONG – Aeterna Zentaris Inc. and Sinopharm A-think Pharmaceuticals Co. Ltd. signed an exclusive license and technology transfer agreement allowing Sinopharm A-think to develop, manufacture and commercialize Aeterna Zentaris' zoptarelin doxorubicin (AEZS-1-8) in China, Hong Kong and Macau. The drug is being developed to treat endometrial cancer.
HONG KONG – Carsgen, a Chinese developer of cancer therapies, announced its completion of an undisclosed series A financing led by China-based health care private equity fund BVCF Management Ltd. The proceeds will be used to initiate the clinical trials of Carsgen's lead therapeutic asset.
